Metabolic characteristics and pharmacokinetic differences of Qiwei Tongbi oral liquid in rheumatoid arthritis rats
© 2022 John Wiley & Sons, Ltd..
Qiwei Tongbi oral liquid (QWTB), a classical traditional Chinese medicine formula, is widely used to treat arthritis-related diseases in clinical practice. Currently, in vivo metabolic characteristics and pharmacokinetic studies are lacking. This study analyzed the prototype components of QWTB absorbed in the blood and their metabolic transformation process after intragastric administration and compared the differences in pharmacokinetic properties between healthy and rheumatoid arthritis model rats. In sum, 17 prototype components and 21 related metabolites were identified in the plasma and urine of the treated rats. Metabolites were derived from sinomenine and magnoflorine. Through systematic methodology verification, an accurate and stable detection method for sinomenine and magnoflorine in plasma samples was established and applied to pharmacokinetic research of QWTB. At the three dose levels, the AUC0-∞ (area under the curve) of the two components showed a good positive correlation with the dose (R2 > 0.9). Compared with healthy rats, the Tmax , t1/2z , and AUC of sinomenine were markedly increased, and Cmax was decreased in rheumatoid arthritis model rats, indicating that the rate of absorption and elimination rate decreased, but the body exposure increased. However, there were no significant differences in the pharmacokinetic parameters of magnoflorine under healthy and pathological conditions. In summary, the main active ingredients of QWTB are sinomenine and magnoflorine, which exhibit linear kinetic characteristics within a set dose range, and the rheumatoid arthritis pathological state is more conducive to the absorption and efficacy of sinomenine. The results of this study demonstrate the rationality of the clinical application of the QWTB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Biomedical chromatography : BMC - 36(2022), 7 vom: 29. Juli, Seite e5375 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qian, Mengyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drugs, Chinese Herbal |
|---|
| Anmerkungen: |
Date Completed 15.06.2022 Date Revised 15.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/bmc.5375 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338783717 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338783717 | ||
| 003 | DE-627 | ||
| 005 | 20231226001438.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/bmc.5375 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1129.xml |
| 035 | |a (DE-627)NLM338783717 | ||
| 035 | |a (NLM)35348242 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qian, Mengyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolic characteristics and pharmacokinetic differences of Qiwei Tongbi oral liquid in rheumatoid arthritis rats |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.06.2022 | ||
| 500 | |a Date Revised 15.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons, Ltd. | ||
| 520 | |a Qiwei Tongbi oral liquid (QWTB), a classical traditional Chinese medicine formula, is widely used to treat arthritis-related diseases in clinical practice. Currently, in vivo metabolic characteristics and pharmacokinetic studies are lacking. This study analyzed the prototype components of QWTB absorbed in the blood and their metabolic transformation process after intragastric administration and compared the differences in pharmacokinetic properties between healthy and rheumatoid arthritis model rats. In sum, 17 prototype components and 21 related metabolites were identified in the plasma and urine of the treated rats. Metabolites were derived from sinomenine and magnoflorine. Through systematic methodology verification, an accurate and stable detection method for sinomenine and magnoflorine in plasma samples was established and applied to pharmacokinetic research of QWTB. At the three dose levels, the AUC0-∞ (area under the curve) of the two components showed a good positive correlation with the dose (R2 > 0.9). Compared with healthy rats, the Tmax , t1/2z , and AUC of sinomenine were markedly increased, and Cmax was decreased in rheumatoid arthritis model rats, indicating that the rate of absorption and elimination rate decreased, but the body exposure increased. However, there were no significant differences in the pharmacokinetic parameters of magnoflorine under healthy and pathological conditions. In summary, the main active ingredients of QWTB are sinomenine and magnoflorine, which exhibit linear kinetic characteristics within a set dose range, and the rheumatoid arthritis pathological state is more conducive to the absorption and efficacy of sinomenine. The results of this study demonstrate the rationality of the clinical application of the QWTB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Qiwei Tongbi oral liquid | |
| 650 | 4 | |a magnoflorine | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a sinomenine | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 700 | 1 | |a Gao, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xialin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiajia |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Huifang |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedical chromatography : BMC |d 1987 |g 36(2022), 7 vom: 29. Juli, Seite e5375 |w (DE-627)NLM012669806 |x 1099-0801 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:7 |g day:29 |g month:07 |g pages:e5375 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/bmc.5375 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 7 |b 29 |c 07 |h e5375 | ||